Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6196 to 6210 of 7707 results

  1. Attention deficit hyperactivity disorder in children and young people: guanfacine prolonged-release (ESNM70)

    This evidence summary has been updated and replaced by NICE guideline NG87.

    Evidence summary
    Published
    22 March 2016

  2. Moderate to severe acute post­-operative pain: sufentanil sublingual tablet system (ESNM71)

    This evidence summary has been withdrawn because the product is no longer available in the UK.

    Evidence summary
    Published
    30 March 2016

  3. Chronic obstructive pulmonary disease: tiotropium/olodaterol (Spiolto Respimat) (ESNM72)

    This evidence summary has been updated and replaced by NICE guideline 115.

    Evidence summary
    Published
    10 May 2016

  4. Chronic obstructive pulmonary disease: olodaterol (ESNM54)

    This evidence summary has been updated and replaced by NICE guideline 115.

    Evidence summary
    Published
    3 February 2015

  5. Asthma: tiotropium (Spiriva Respimat) (ESNM55)

    This evidence summary has been updated and replaced by NICE guideline NG80.

    Evidence summary
    Published
    3 March 2015

  6. Glaucoma: brinzolamide/brimonidine combination eye drops (ESNM56)

    This evidence summary has been updated and replaced by NICE guideline NG81.

    Evidence summary
    Published
    17 March 2015

  7. Chronic obstructive pulmonary disease: aclidinium/formoterol (ESNM57)

    This evidence summary has been updated and replaced by NICE guideline 115.

    Evidence summary
    Published
    28 April 2015

  8. Ulcerative colitis: budesonide multimatrix (Cortiment) (ESNM58)

    This evidence summary has been updated and replaced by NICE guideline NG130.

    Evidence summary
    Published
    16 June 2015

  9. Type 2 diabetes: dulaglutide (ESNM59)

    This evidence summary has been updated and replaced by NICE guideline NG28.

    Evidence summary
    Published
    16 June 2015

  10. Moderately to severely active ulcerative colitis: adalimumab (ESNM6)

    This evidence summary has been replaced by NICE technology appraisal guidance 329.

    Evidence summary
    Published
    2 November 2012

  11. Long-acting reversible contraception: levonorgestrel 13.5 mg intrauterine delivery system (ESNM41)

    This evidence summary has been replaced by the long-acting reversible contraception: implementation resource summary.

    Evidence summary
    Published
    4 June 2014

  12. Hospital-acquired pneumonia caused by methicillin-resistant Staphylococcus aureus: telavancin (ESNM44)

    This evidence summary has been withdrawn because the product is no longer available in the UK.

    Evidence summary
    Published
    15 July 2014

  13. Alcohol dependence: nalmefene (ESNM29)

    This evidence summary has been replaced by NICE technology appraisal guidance 325.

    Evidence summary
    Published
    17 December 2013

  14. Asthma: fluticasone/formoterol (Flutiform) combination inhaler (ESNM3)

    This evidence summary has been updated and replaced by NICE guideline NG80.

    Evidence summary
    Published
    12 October 2012

  15. Prostate cancer: triptorelin (Decapeptyl SR) (ESNM30)

    This evidence summary has been updated and replaced by NICE guideline NG131.

    Evidence summary
    Published
    13 January 2014